~~<i id='6FC566DFE4'><strike id='6FC566DFE4'><tt id='6FC566DFE4'><pre id='6FC566DFE4'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：explore 2025-10-06 12:10:36 Page View：246

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： STAT wants to know your pick for a great summer read or listen
Next article： In Memoriam: Notable people who died in 2023

explore

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

UnitedHealth CEO's Medicaid comments send insurer stocks diving

UnitedHealthGroupCEOAndrewWittysaidthecompanywasbeginningtoseea“disturbance”initsMedicaidmedicalcost